Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;59(2):796-802.
doi: 10.1128/AAC.03876-14. Epub 2014 Nov 17.

16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis

E Amram  1 , I Mikula  2 , C Schnee  3 , R D Ayling  4 , R A J Nicholas  4 , R S Rosales  4 , S Harrus  5 , I Lysnyansky  6
Affiliations

16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis

E Amram et al. Antimicrob Agents Chemother. 2015 Feb.

Abstract

Mycoplasma bovis isolates with decreased susceptibilities to tetracyclines are increasingly reported worldwide. The acquired molecular mechanisms associated with this phenomenon were investigated in 70 clinical isolates of M. bovis. Sequence analysis of the two 16S rRNA-encoding genes (rrs3 and rrs4 alleles) containing the primary binding pocket for tetracycline (Tet-1 site) was performed on isolates with tetracycline hydrochloride MICs of 0.125 to 16 μg/ml. Mutations at positions A965T, A967T/C (Escherichia coli numbering) of helix 31, U1199C of helix 34, and G1058A/C were identified. Decreased susceptibilities to tetracycline (MICs, ≥2 μg/ml) were associated with mutations present at two (A965 and A967) or three positions (A965, A967, and G1058) of the two rrs alleles. No tet(M), tet(O), or tet(L) determinants were found in the genome of any of the 70 M. bovis isolates. The data presented correlate (P<0.0001) the mutations identified in the Tet-1 site of clinical isolates of M. bovis with decreased susceptibility to tetracycline.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Distribution of Mycoplasma bovis isolate MICs to tetracycline. MICs of tetracycline tested in this study are shown on the x axis; the number of M. bovis isolates corresponding to each MIC is shown on the y axis.
See this image and copyright information in PMC

References

    1. Nicholas RA, Ayling RD. 2003. Mycoplasma bovis: disease, diagnosis, and control. Res Vet Sci 74:105–112. doi:10.1016/S0034-5288(02)00155-8. - DOI - PubMed
    1. Giguere S. 2007. Tetracyclines and glycylcyclines, p 231–240. In Giguere S, Prescott JF, Baggot JD, Walker RD, Dowling PM (ed), Antimicrobial therapy in veterinary medicine, 4th ed. Wiley Blackwell, Hoboken, NJ.
    1. Brysker A. (ed). 2005. Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC.
    1. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260. doi:10.1128/MMBR.65.2.232-260.2001. - DOI - PMC - PubMed
    1. Roberts MC, Koutsky LA, Holmes KK, LeBlanc DJ, Kenny GE. 1985. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences. Antimicrob Agents Chemother 28:141–143. doi:10.1128/AAC.28.1.141. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources